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Abstract: The Human Papilloma Virus (HPV) infection is now more com-
mon sexually transmitted diseases, with an incidence of 5.5 million worldwi-
de, with 85% of the carrier of this virus adult population. Their oncogenic 
potential and increased oral lesions associated with oral HPV infection have 
led us to make a narrative review of the literature on the role of HPV in 
oral cancer, especially types 16 and 18. Here we refer to the possible routes 
of infection, oncogenic mechanisms, both benign and potentially malignant 
oral lesions associated with the infection, different methods used for detec-
tion, prediction and prevention of infection. We stress the importance of the 
role of the dentist to identify individuals considered high risk and ease of 
performing detection in the oral cavity, through a quick and easy method as 
exfoliative cytology.
Keywords: Oral cavity, squamous cell carcinoma, HPV 16, HPV 18.                             
INTRODUCTION.
The Human Papilloma Virus (HPV) is the most 
common sexually transmitted infection in the world. It 
has an incidence of 5.5 million people worldwide1 and 
85% of the adult population would be carrier of this 
virus. However, this does not necessarily mean they have 
some kind of injury.
HPV consists of a double-stranded DNA containing 
8,000 pairs of bases covered by a non-enveloped capsid 
in which three regions are identified. The first one is 
called “EarlyRegion”. It corresponds to 45% of the viral 
genome and E1, E2, E4, E5, E6 and E7 genes2, which are 
responsible for cellular regulation and transformation, 
can be found in it3. The second one is called “Late 
Region”. It corresponds to 40% of the viral DNA and 
L1 and L2 genes, which encode viral capsid proteins, are 
found in it. The latter, called “Third Region LCR” or 
“Long Control Region” is responsible for regulating cell 
functions2 (Table 1). This virus has a variation in the E6 
and E7 genes and this allows to identify more than 120 
subtypes of HPV3, which are classified according to their 
oncogenic potential (Table 2)1.
These various subtypes of HPV can cause benign, 
potentially malignant and malignant injuries in the 
skin, the anogenital area, the oral cavity and especially 
in the oropharyngeal area. In 1907, HPV infection was 
associated to benign lesions for the first time. Then, in 
1976, ZurHausen proposed that HPV has a causal role in 
cervical cancer and, in 1983, Syrjanen et al. proposed it 
has a role in head and neck cancers4. Among the benign 
lesions, there are the papilloma, vulgar wart and the 
condylomata acuminatum3. Dysplastic and neoplastic 
lesions were mainly associated with HPV subtype 16. 
From among these lesions, the squamous cell carcinoma 
(SCC) of the oropharynx is mainly highlighted5. This 
is based primarily on the epitheliotropic characteristics 
of HPV, because of the morphological resemblance 
between the genital and oropharyngeal epithelium and 
the etiologic role this virus has in cervical cancer4. 
The importance of determining the presence and type 
of HPV in oral and pharyngeal samples of SCC is based 
on existing epidemiological, histopathological, molecular 
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TYPE  OF  ONCOGENIC RISK  TYPES  OF  HUMAN  PAPILLOMA  VIRUS
High 16, 18
Intermediate 31, 33, 35, 39, 45, 51, 52, 58
Low  6, 11, 42, 43, 44
FUNCTION 
E1  Initiation of DNA replication and transcription. 
E2  Control of DNA replication and transcription. 
E4  Cytoskeleton disruption.
E5  Interaction with cellular proteins. 
E6  Degraded p53.
E7  Rb protein binding. 
L1  It encodes viral capsid proteins for the production of new virus. 
L2  It encodes viral capsid proteins for the production of new virus.
Table 1. Viral genome and protein functions1.
Table 2. Human Papilloma virus genotype and its oncogenic risk1.
Table 3. Difference  between HPV positive and HPV
 negative  oropharyngeal  cancer1.
Table 4. HPV  associated  oral  lesions  diagram 3,12.
BENIGN  POTENTIALLY  MALIGNANT 
 LESIONS MALIGNANT LESIONS  LESIONS
Squamous papilloma Leukoplakia Spinous 
  cell carcinoma
Verruca vulgaris
Condyloma acuminatum
Focal epithelial 
hyperplasia
and even post treatment evolution differences between 
different samples or SCC which are or not associated 
with HPV infection. These differences can be observed 
in Table 31. According to the above, it can be inferred that 
SCC samples associated with HPV have a less aggressive 
biological behavior.
The increase in HPV-associated oral lesions and 
their consequent oncogenic potential has led to make 
a narrative literature review regarding HPV and its 
role in oral cancer. Below, it talks about the possible 
routes of infection, oncogenic mechanisms, oral lesions 
associated with the infection (benign potentially 
malignant and malignant), different methods used for 
its detection, prognosis and prevention, highlighting 
the role dentists plays. Finally, there will be authors’ 
comments on the issue.
HPV FEATURES.
Transmission.
The mode of transmission of HPV to the oral mucosa 
is not clearly known yet. The infection usually starts 
early in life and it has been demonstrated the presence of 
this virus in 6% of children, 13% of adolescents and 23% 
of adults2. It can be spread vertically and/or horizontally. 
The first one is a perinatal transmission of cervical 
origin. The second one, which is considered as the 
primary means of transmission, is sexual and is caused 
through oro-genital contact producing micro traumas in 
the mucosal when in contact with the virus3. 
Recently, HPV has been detected in histopathology 
sections of most patients diagnosed with oral cancer and 
who have a sexual history linked to more than one sexual 
partner, coupled with oro-genital contact, compared with 
histopathology sections of patients who have also been 
diagnosed with oral cancer but have not participated 
in these kind of practices. Therefore, this could be 
considered as important data in the virus transmission6. 
HPV infects squamous cells because it has an affinity 
for the epithelium7, which is where virus replication takes 
place. This depends on the proteins encoded by the viral 
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 HPV POSITIVE  HPV NEGATIVE
AGE 30-50 YEARS OLD 50-80 YEARS OLD
Risk factor  Number of sexual part- Cigarettes  and
 ners, history of sexually  alcohol.
 transmitted disease.
Incidence  Increasing  Decreasing .
Location Base of tongue, tonsil.  Oral mucosa .
Field No.  Yes.
cancerization
Histology  Basaloid, poor  Different degrees 
 differentiation. of differentiation.
Biomarker p16 overexpression,  p16 loss, pRb muta-
 p16 and pRb inacti- tion, overexpression
 vation. of epidermal growth  
  factor.
Chromosome  Less frequent. Frequent .
Mutation 
Prognosis Very good, good respo- Variable.
 nse to chemotherapy 
 and radiotherapy. 
Metastasis  Rare Frequent.
5-year 60-90% 20-70%
survival rate
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genome and the differentiation degree of the infected 
cell3. First, HPV infects the basal epithelium cells, 
but there is a limited expression of viral genes in these 
cells and additional genes of the virus start expressing 
as epithelial cells differentiate7-8. Mature virions are 
produced in the granular layer, resulting in perinuclear 
vacuolization which is a characteristic of the epithelial 
cells called koilocytes, which are finally released into the 
stratum corneum7. 
Oncogenic mechanism.
HPV infection was first associated with cervical cancer 
and it has been found that the Papilloma Virus 16 and 18 
are mainly involved9.
 The possibility for the Human Papilloma Virus be-
coming involved in carcinogenic mechanism depends on 
the type of virus which infects the epithelial cell, the sy-
nergistic action with different agents (physical, chemical 
and/or biological), genetic constitution and the host res-
ponse immune3. 
High oncogenic risk viruses insert their viral genome 
into the host keratinocytes. The integrated part of the viral 
genome into the cell corresponds to E1, E6 and E7 regions, 
while E2, E3, E4 and E5 regions get lost (Table 1). The loss 
of E2 region during the integration process results in loss of 
control of  the E6 and E7 regions, which are directly related 
with the cell cycle, by inhibiting the normal functions 
of the p53 and pRB proteins, respectively. These two 
proteins regulate normal cell division. The first produces 
transcription factors required for progression through the 
cell cycle. This denotes that RB prevents the cell from 
dividing until enough proteins have been isolated for cell 
division. E2F is the protein which produces Rb, making 
it a suppressor gene which prevents the cell cycle from 
continuing. When HPV infects a cell, E7 gene binds to 
Rb so that it releases E2F gene, being an advance signal for 
the cell cycle. So, as long as E7 gene remains stationary to 
Rb, the cell cycle continues in an uncontrolled way, which 
is a characteristic of malignancy8. Furthermore, when the 
DNA of a cell is damaged, p53 stops cellular division and 
repairs DNA. If this is not possible, this protein induces 
apoptosis, ensuring that the damaged cell dies and is not 
reproduced. The viral protein E6 can bind to p53 and 
inactivate it. This allows the virus to replicate in the cell, 
since p53 gene, inhibited by the virus, cannot stop it or 
start the process of cell death8-9.
The role of the immune response against HPV is 
unclear3. This response is cellular and humoral. The first 
one is characterized by the involvement of natural killers, 
CD4 lymphocyte inducing an adaptive immune cytotoxic 
response mainly directed to the early E6 and E7 proteins10. 
Regarding the humoral response, IgA, IgM or IgG 
antibodies reach their maximum values 6 to 12 months 
after being infected3-11. Antibodies are raised against the 
viral capsid proteins and early viral proteins including 
the E6 and E7 oncogenic proteins7-11. The presentation 
of viral antigens mediated by cells is so minimal that the 
infection can be maintained for months or years without 
being detected clinically. Therefore, the absence of clinical 
evidence is not synonymous of the virus absence12.
Oral manifestations associated with  human 
papilloma  virus  infection.
The presence of HPV in the oral mucosa is associa-
ted with benign, potentially malignant and malignant 
lesions. Table 43-12. 
BENIGN LESIONS.
Squamous papilloma.
It corresponds to a papillary growth of the squamous 
epithelium13 and is mainly associated with HPV types 6, 
1113-14 and HPV 1813. 
It presents an estimated prevalence of 1 in 250 adults13. 
This injury is more common in children and has the same 
frequency in men and women. It is preferably found in 
the soft palate, tongue and lips. However, other areas of 
the oral mucosa can be affected as well.
Clinically, an increased soft exophytic mass with nu-
merous verrucoid projections, pedunculated, normal co-
lor, white or slightly red, asymptomatic and approxima-
tely 0.5 cm diameter is observed.
Histopathologically, an intense proliferation of squa-
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mous epithelium in papillary growth with projections su-
rrounding connective tissue is seen. Generally, the basal 
epithelial layer has hyperplasia, mitotic activity which 
may involve higher strata. Also, sometimes koilocytes 
can be observed in the spinosum stratum, corresponding 
to clear epithelial cells with pyknotic nuclei altered by 
viral infection15. 
Verruca vulgaris. 
Common wart is the most prevalent injury of different 
HPV-associated lesions and affects both the skin and the 
oral mucosa. The most affected areas in the oral mucosa 
are keratinized, i.e., the hard palate and gingiva and this 
is because of their histological similarity to the skin. HPV 
types which are more closely associated with oral mucosal 
warts are 2, 4 and 5716. 
Clinically, a papule or nodule with papillary projections 
is observed. It may be sessile or pedunculated. Most of 
them are white but they can also be pink. 
Histologic features include intense epithelial proliferation 
with papilliform projections on the connective tissue, 
hypergranulosis and koilocytes in the spinous layer16.
Condyloma acuminate.
It is a warty lesion associated with infection due to 
HPV 6 and 11 and occurs in the oral and anogenital mu-
cosa. In adults, it is sexually transmitted and can be pas-
sed on through contaminated objects in children under 
two years old5.
The oral lesions are usually in the labial mucosa, soft pala-
te and lingual frenulum. It is seen as a well-defined exophytic 
mass. It is sessile, pink and tends to be larger than the com-
mon wart (1 to 1.5 cm). 
Histopalogic features include intense epithelial prolife-
ration with papillary projections and crypts of keratin bet-
ween them. Koilocytes are observed in the surface layers 
and these are less prominent than in genital lesions15. 
Focal epithelial hyperplasia.
This lesion was first described as multiple nodules 
in the oral mucosa in 1965 by Archar et al. It is more 
prevalent in children in India (37%) and has been 
associated with HPV types 13 and 32. 
It affects the labial mucosa, buccal and lingual and 
multiple rounded nodular lesions with f lat surface and 
pale pink are observed. 
Histopathologically, it can be observe a hyperplasia 
of stratified squamous epithelium, thick and elongated 
ridges, koilocytes in the surface layer and sometimes 
nuclei of the keratinocyte are altered resembling mitotic 
figures15-16. 
POTENTIALLY MALIGNANT LESIONS (CAN-
ZERISABLE).
The presence of HPV in potentially malignant 
lesions is important because it suggests the possibility of 
playing an important role in malignant transformation, 
which highlights the non-homogeneous leukoplakia. It 
is estimated that the prevalence of this virus in these 
lesions ranges from 0 to 85% and is mainly associated 
with virus type 16 and 182-17. This wide variation in 
the range may be related to demographic variables, 
differences in the categorization of the studied lesions, 
differences in sampling, as well as the sensitivity of the 
technique employed for molecular detection2. 
The role this virus plays in oral leukoplakia, as well 
as in its pathogenesis and malignant transformation, is 
unclear. But this mechanism can be explained through 
the action of HPV E6 and E7 proteins which promote 
keratinocyte to recommence the S phase of the cell 
cycle resulting in altered epithelial proliferation and 
maturation2,3,12,18,19. 
The most frequent morphologic features in HPV asso-
ciated with dysplasia are the presence of eosinophilic cells 
distributed throughout the thickness of the epithelium, due 
to the presence of apoptosis and cytological changes such as 
hyperchromatism20.
MALIGNANT LESIONS.
The presence of intraoral SCC associated with HPV is 
specially set up at the base of the tongue2,6,17,19. Neverthe-
less, when considering the larynx and oropharynx, it is 
more frequent in the last one. When determining the pre-
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valence of HPV associated with these different areas with 
presence of SCC, it is statistically significantly higher in 
the oropharynx (48.5%) than in the oral cavity (32.5%) 
and larynx (30%). When comparing its presence in rela-
tion to different geographical areas, it has been reported 
that Asia has a prevalence of 49.1%, Europe 25.6% and 
America 23.8%21. 
By observing these data, it can be inferred that there is 
a high incidence of HPV infection in patients with SCC, 
suggesting it has a relevant role in its etiology. The lar-
gest association of HPV infection in the oropharynx can 
be understood by the morphological difference with the 
epithelium of the oral cavity and its similarity with the 
epithelial and lymphoid tissue in the uterine endocervix. 
Furthermore, the differences registered in location can be 
attributed to different ethnic groups, the environment, 
lifestyle and health conditions. In Europe and America, 
it is primarily associated with sexual activity and number 
of partners21. 
According to an analysis by the International Agency 
for Research on Cancer (IARC), there is an increased in-
cidence of cancer in the world’s poorest regions: Africa, 
Southeast Asia, India and Latin America. Also, there are 
divisions among their socioeconomic levels in each coun-
try, showing that men from most vulnerable groups have 
a greater risk of developing and dying from oropharyn-
geal cancer and the most vulnerable women are at higher 
risk of contracting and dying from esophageal cancer22.
The main types of virus associated with the genesis of 
SCC are high risk, especially types 16 and 1823 and less 
frequently types 8, 31, 38 and 66. Regarding the presen-
ce of HPV specifically types 16 and 18, in the study by 
Kreimer et al., it was found that out of 2642 biopsies of 
SCC of head and neck, 16% were positive for HPV16 
and 3.9% at 18 and 23.5% was associated with SCC spe-
cifically in the oral cavity and the oropharynx 36.5%6-24. 
Patients with oropharyngeal cancer associated with 
HPV are characterized by being younger (5-10 years) 
than patients with carcinomas not associated with HPV. 
They are usually not smokers or alcohol drinkers and the 
risk of developing it is equal in men and women23.
DETECTION METHODS.
There is no standard method for the detection of HPV 
in the oral cavity. However, currently, virological labo-
ratories provide a kit containing a sterile cytology brush 
and a tube for transportation. Then, the oral mucosa is 
brushed and it is possible to obtain epithelial cells where 
viral DNA is detected through chain reaction (PCR). It is 
important to highlight the quality of the nucleic acids in 
formalin-fixed paraffin-embedded samples is low. The-
refore, it is not recommended to obtain viral DNA from 
these samples25. 
Other molecular techniques, such as in situ hybridiza-
tion and Southern Blott, are known for detecting nuclear 
DNA. But,from among these different types of methods, 
it is preferably to use PCR, since it has been seen that the 
other types of procedures mentioned detected a lowera-
mount of viral DNA6.
PROGNOSIS.
SCC associated with the presence of  HPV has a better 
prognosis11,24,26 and a lower mortality rate than the one 
which is not associated with HPV13. The reason for this is 
unclear. However, this might be explained by the ability 
of HPV positive cancer cells to produce apoptosis in res-
ponse to DNA damage. Another reason could be the in-
ability to induce neoplastic transformation in uninfected 
cells into cancer cells. Thus, it is easy to understand why 
a HPV-positive SCC does not induce multifocal lesions11.
PREVENTION.
Prevention of HPV infection has recently been achie-
ved by developing vaccines based on the use of virus-like 
particles (VLP). VLP are obtained by synthesis and auto-
assembly in vitro of the main proteins of major capsid of 
HPV virus. These are morphologically identical to HPV 
virions but do not contain viral DNA and this means 
that they cannot transmit the virus or cause disease, but 
do induce the generation of neutralizing antibodies and 
Human Papilloma Virus and oral cancer: 
Narrative review of the literature.
Fernández A, Marshall M & Esquep A.
J Oral Res 2014; 3(3): 190-197
195ISSN Online 0719-2479 - ©2014 - Official publication of  the Facultad de Odontología, Universidad de Concepción - www.joralres.com
confer protection against HPV.
There are two types of prophylactic vaccines: Bivalen-
te Cervarix, which protects against types 16 and 18 and 
Quadrivalent Gardasil, which protects against types 6, 
11, 16 and 18. These vaccines are administered intramus-
cularly in three doses, at two and six months respectively 
after the initial dose and are effective for 3 to 5 years2.
Depending on the natural history of HPV infection and 
mainly cervical neoplasia, it seems logical that vaccination 
would be before initiation of sexual activity. The Advisory 
Commite on Immunization Practice (ACIP) recommends 
that primary vaccination is done between 11-12 years old, 
but there is also a range between 9 to 26 years approved by 
the Food and Drug Administration (FDA)27. 
Herrero et al. reported that vaccination against high-
risk subtypes (16 and 18) decreases the prevalence of the 
oral infection. It is estimated that the efficacy of vaccina-
tion would be about 93% (95% CI 62.2% to 99.7%). The 
author also suggested that the vaccine is effective when 
given to patients who have not been exposed to HPV28.
It must be considered that these vaccines are not a 
treatment for infections. Instead, they provide a benefit 
if the person receives it before being sexually active13.
Routine vaccination programs have been implemented 
in several countries with satisfactory results. Australia 
showed that a routine program for men and women is 
effective and successful, proving a reduction of 77% of 
genital warts for women in the age range of 12-17 years 
old and a reduction of 44% is observed in men. The same 
results were observed in Rwanda, Africa. It has been 
observed that vaccination against HPV-16 to prevent 
the infection of the uterine cervix would also have an 
effect on the infection by HPV-16 at oral level. However, 
further studies are needed to confirm this theory29. 
FINAL COMMENT. 
The relationship between HPV infection and cervical 
cancer has been well established and its presence has been 
observed in 90% of intraepithelial neoplasias. This has 
increased interest in discovering whether there is a posi-
tive association between HPV infection and oral cancer. 
Despite several studies on this subject, the results are not 
conclusive to date. For example, Kreimet et al. found a 
prevalence of 24% of HPV presence in SCC, while other 
studies have found that the prevalence of HPV-associated 
oropharyngeal cancer is 35%. Näsman et al. observed an 
increased incidence among tonsillar cancer associated 
with the presence of HPV, 23% in 1970 to 93% in 200724. 
A study by Lopes et al. attempted to establish the preva-
lence and relationship between the research of  HPV and 
HPV 16-18 in oral carcinomasby using PCR and Q-PRC. 
This study suggested that HPV, as anoncogenic factor, is 
uncommon and only high viral load numbers would have 
a causal relationship30.
In Chile, both in SciELO Chile and the Health Minis-
try database, there are no available epidemiological data 
on oral lesions associated with HPV. So, we are working 
on keratinized mucous detection in both groups with and 
without factors risk. However, in data obtained from the 
IARC about incidence and mortality of the oral cavity 
cancer in South America, it is observed that the incidence 
for men is 2.5% while the mortality rate is 1.8%. The in-
cidence for women is 1.4%, and the death rate is 0.9%31.
It is noteworthy that this year the vaccine against HPV 
will be incorporated as part of the national immuniza-
tion program, benefiting all girls aged 9. It will be ad-
ministered in schools and then be reinforced in a year in 
order to protect from cervical and oropharyngeal cancer. 
Although the development of genital lesions associated 
with HPV is more important in women, vaccinating men 
could also be promoted since indicators of oral health 
show some increase in oral SCC and HPV involvement.
 Considering and highlighting the major route of vi-
rus inoculation is sexual and it is asymptomatic, it would 
require significant health policies and appropriate pre-
ventive efforts which involve both the medical and den-
tal profession. Therefore, a correct history and clinical 
examination by the dentist in order to identify indivi-
duals considered high risk, such as those who start their 
sexual history early, have promiscuous sexual behavior, 
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oral-genital contact, and history of warty lesions in other 
anatomic areas, is important.
Because of  the  association of  this virus with the deve-
lopment of potentially malignant lesions and oral carci-
nomas, it is recommended to primarily search throughout 
verrucoide like injuries, as this virus tends to produce 
epithelial proliferation and malignancy and in every ma-
lignant lesion of epithelial nature. This can be done quic-
kly and easily in the clinic by a general dentist using a 
kit with a cytology brush provided by laboratories which 
then confirms its presence through PCR tests.
Finally, the importance of promoting sex education 
campaigns and prevention with the vaccine against the 
virus can be highlighted. It has been noted in literatu-
re that the creation of public policies on education and 
awareness about HPV are primary preventive measures 
which have a large social impact, are effective and simple 
to develop.  In the gynecological area, prevention of HPV 
infection is widely described in literature, but not in the 
dental area29.
Virus Papiloma Humano y cáncer oral: Revisión 
narrativa de la literatura.
Resumen: El Virus Papiloma Humano (VPH) en la ac-
tualidad constituye la infección por transmisión sexual más 
frecuente, presentando una incidencia de 5,5 millones en el 
mundo, siendo un 85% de la población adulta portadora de 
este virus. Su potencial oncogénico y el aumento de lesiones 
orales asociadas a infección oral por VPH nos han llevado 
a realizar una narración de la literatura referente al rol del 
VPH en el cáncer oral, especialmente de los subtipos 16 y 18. 
Nos referiremos a sus posibles vías de contagio, mecanismos 
oncogénicos, lesiones orales tanto benignas como potencial-
mente malignas asociadas a su infección, diferentes métodos 
utilizados para su detección, pronóstico y prevención de con-
tagio. Destacamos la importancia del rol del odontólogopara 
identificar individuos considerados de alto riesgo y la facili-
dad de realizar sudetección en la cavidad oral, a través de un 
método rápido y sencillo como es la citología exfoliativa.
Palabras clave: cavidad bucal, carcinoma espinocelular, 
VPH 16, VPH 18. 
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